targets

It is patently obvious that CNS activity (and trans-cellular permeability in general) is a complex function of physical/chemical properties of molecules such as size, lipophilicity, hydrogen-bonding potential, charge, and conformation.

A unique collection of 1490 anti-virus compounds effective for new anti-virus drugs high throughput screening and high content screening;

A unique collection of 718 compounds targeting lipid metabolism, can be used for high-throughput screening (HTS) and high-content screening (HCS).

A unique collection of 2154 compounds related to neurodegenerative diseases can be used for HTS or HCS;

A unique collection of 3064 compounds in clinical trial phases for high throughput screening (HTS) and high content screening (HCS);

A collection of 19650 small molecule compounds with validated activity for high throughput screening (HTS), high content screening (HCS), cell induction, and target identification;

Well-chosen quantity: only contains 989 bioactive compounds after careful selection

A unique collection of 1960 FDA approved drugs for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 950 promising or approved mitochondria-targeted compounds including Idebenone, the only approved drug targeting mitochondria, for research in mitochondrial medicine;

A collection of 1321 TCM monomers with anti-inflammatory activity or targeting molecular therapeutic targets in inflammation, a powerful tool for drug discovery and mechanism study;

A unique collection of 1072 compounds derived from traditional Chinese medicines (TCMs) for promoting blood circulation and removing blood stasis.

A unique collection of 693 rare natural products, which can be used for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 1796 annotated bioactive compounds with clear targets, suitable for phenotypic screening;

For your convenience, there are Diversity Sets of 5,000, 10,000, 15,000, and 20,000 compounds with no structure overlap.

The unparalleled chemical diversity of natural products makes them an ideal choice for screening active small molecules. Natural products is always a significant source in drug discovery. According to authoritative statistics, 79 out of 99 small molecule anticancer drugs have been successfully developed based on natural products since 1981. Natural products have demonstrated successful modulation of isolated but crucial targets, especially in antimicrobial targets and protein interactions. Many researchers consider natural products and their derivatives as unique tools for studying and manipulating protein function. The Drug-like Natural Compound Library comprises 522 novel molecules, serving as a complement to the L6000 Natural Product Library. This library enhances the probability of successful drug screening, making it an excellent tool for lead compound discovery.

A unique collection of 680 EMA-approved drugs for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 1150 cytoskeleton-related compounds, can be used for HTS and HCS;

A unique collection of 1133 compounds with confirmed anti-SARS-CoV-2 activity or potential activity and part of them are broad-spectrum antiviral agents;

A unique collection of 9730 inhibitors for research in cell signaling, high throughput screening (HTS) and high content screening (HCS) for new drugs;

A unique collection of 1268 cancer cellular metabolism related compounds for cancer research and high throughput screening (HTS) and high content screening (HCS);

122 tumor-targeted drugs that can be used for high-throughput and high-content screening.

A unique collection of 523 compounds acting on immune-oncology therapeutic targets can be used for high throughput and high content screening;